DK0969865T3 - Systemer til præsentation af MHC-antigener af klasse II og fremgangsmåder til aktivering af CD4+-T-celller - Google Patents

Systemer til præsentation af MHC-antigener af klasse II og fremgangsmåder til aktivering af CD4+-T-celller

Info

Publication number
DK0969865T3
DK0969865T3 DK97927709T DK97927709T DK0969865T3 DK 0969865 T3 DK0969865 T3 DK 0969865T3 DK 97927709 T DK97927709 T DK 97927709T DK 97927709 T DK97927709 T DK 97927709T DK 0969865 T3 DK0969865 T3 DK 0969865T3
Authority
DK
Denmark
Prior art keywords
cells
methods
activating
systems
presenting
Prior art date
Application number
DK97927709T
Other languages
English (en)
Inventor
Lars Karlsson
Michael R Jackson
Susan R Webb
Ola Winqvist
Per A Peterson
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK0969865T3 publication Critical patent/DK0969865T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
DK97927709T 1996-05-23 1997-05-22 Systemer til præsentation af MHC-antigener af klasse II og fremgangsmåder til aktivering af CD4+-T-celller DK0969865T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1817596P 1996-05-23 1996-05-23
PCT/US1997/008697 WO1997046256A1 (en) 1996-05-23 1997-05-22 Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells

Publications (1)

Publication Number Publication Date
DK0969865T3 true DK0969865T3 (da) 2007-03-19

Family

ID=21786645

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97927709T DK0969865T3 (da) 1996-05-23 1997-05-22 Systemer til præsentation af MHC-antigener af klasse II og fremgangsmåder til aktivering af CD4+-T-celller

Country Status (12)

Country Link
US (4) US6355479B1 (da)
EP (1) EP0969865B1 (da)
JP (2) JP5006998B2 (da)
AT (1) ATE347588T1 (da)
AU (1) AU723355B2 (da)
CA (1) CA2254975C (da)
DE (1) DE69737070T2 (da)
DK (1) DK0969865T3 (da)
ES (1) ES2278390T3 (da)
IL (1) IL126843A (da)
PT (1) PT969865E (da)
WO (1) WO1997046256A1 (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737070T2 (de) * 1996-05-23 2007-06-21 The Scripps Research Institute, La Jolla Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
ATE437366T1 (de) 1998-05-11 2009-08-15 Miltenyi Biotec Gmbh Verfahren zur direkten auswahl von antigen- spezifischen t-zellen
US6230662B1 (en) 1998-06-22 2001-05-15 Theresa Miale Animal lift and transport apparatus and method for using the same
WO2000009665A1 (en) * 1998-08-10 2000-02-24 Chiron Corporation Engineered antigen-presenting cells expressing an array of antigens and uses thereof
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
DE69942100D1 (de) * 1998-10-20 2010-04-15 Androclus Technologies S R L I Künstliche antigen-spezifischen zellen und zugehörige verfahren
US6225443B1 (en) * 1999-05-19 2001-05-01 Wisconsin Alumni Research Foundation Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
US7541429B2 (en) 2000-10-10 2009-06-02 The Board Of Regents Of The University Of Oklahoma Comparative ligand mapping from MHC positive cells
DE10009341A1 (de) * 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
AU2000243137A1 (en) * 2000-04-20 2001-11-07 Salvatore Albani Methods for isolation, quantification, characterization and modulation of antigen-specific t cells
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
WO2002056908A2 (en) * 2001-01-16 2002-07-25 Hildebrand William H Artificial antigen-presenting cells
US7579007B2 (en) * 2001-02-13 2009-08-25 Jdm Technologies, Inc. Production of “biological carriers” for induction of immune responses and inhibition of viral replication
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
US20030077248A1 (en) * 2001-02-20 2003-04-24 Ann Moriarty Cell therapy method for the treatment of tumors
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2003057171A2 (en) * 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
ES2282355T3 (es) 2002-10-11 2007-10-16 Sentoclone Ab Inmunoterapia de cancer.
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
JP2007511760A (ja) * 2003-11-03 2007-05-10 ベックマン コールター インコーポレーティッド Ｍｈｃ結合ペプチドを検出するための溶液ベースの方法
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
PL2573166T3 (pl) 2004-02-26 2016-11-30 Sposoby otrzymywania komórek T do terapii komórkowej
EP1766393A4 (en) * 2004-05-07 2008-06-18 Beckman Coulter Inc MHC-BRIDGE SYSTEM FOR DETECTION OF THE CTL-MEDIATED LYSE OF ANTIGEN-PRESENTING CELLS
EP1765988B1 (en) 2004-05-27 2017-09-20 The Trustees of The University of Pennsylvania Novel artificial antigen presenting cells and uses therefor
EP1781313A4 (en) * 2004-06-17 2009-08-26 Beckman Coulter Inc MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
EP1712615A1 (en) * 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
RU2596491C2 (ru) 2005-06-08 2016-09-10 Дана-Фарбер Кэнсер Инститьют Способы и композиции для лечения персистирующих инфекций
US20100080792A1 (en) * 2005-06-16 2010-04-01 Dorothee Herlyn Method for Identifying a MHC Class II-Dependent Tumor-Associated T Helper Cell Antigen
AU2006328945B2 (en) 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
WO2007071389A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating disseminated cancer
WO2007071410A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating urinary bladder cancer
WO2007071388A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
RU2447900C2 (ru) 2006-03-01 2012-04-20 Янссен Фармацевтика Н.В. Лечение рака, комбинирующее лимфоистощающее вещество с цтл и цитокинами
BRPI0720342A2 (pt) * 2006-10-04 2018-09-18 Janssen Pharmaceutica N.V. preparado de células apresentadoras de antígenos artificiais e seu uso em terapias celulares.
JP5623747B2 (ja) * 2006-12-27 2014-11-12 エモリー ユニバーシティ 感染症および腫瘍を処置するための組成物および方法
US20110070154A1 (en) * 2008-08-13 2011-03-24 Hyde Roderick A Artificial cells
WO2010063011A2 (en) 2008-11-28 2010-06-03 Emory University Methods for the treatment of infections and tumors
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
EP2404618A1 (en) 2010-07-07 2012-01-11 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Immunomodulatory protein constructs with a helical polymeric backbone.
WO2012017678A1 (ja) * 2010-08-06 2012-02-09 株式会社ケーナインラボ 免疫機能の強化剤
US9233156B2 (en) 2011-05-03 2016-01-12 Immunovative Therapies Ltd. Induction of IL-12 using immunotherapy
CA2838041C (en) 2011-05-03 2018-09-25 Immunovative Therapies, Ltd. Methods for handling biological drugs containing living cells
WO2013163171A1 (en) 2012-04-24 2013-10-31 Kaufman Dan S Method for developing natural killer cells from stem cells
ES2828982T3 (es) 2013-05-14 2021-05-28 Univ Texas Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
CA2934075C (en) 2013-12-16 2023-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
CN113234757B (zh) 2014-02-14 2024-10-29 得克萨斯州大学系统董事会 嵌合抗原受体及制备方法
WO2015148960A1 (en) 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
EP3134437A1 (en) 2014-04-23 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
KR20160145186A (ko) 2014-04-24 2016-12-19 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
CA2964785A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
US10570186B2 (en) 2014-11-05 2020-02-25 Board Of Regents, The University Of Texas System Chimeric antigen receptors (CAR) to selectively target protein complexes
FR3031519B1 (fr) 2015-01-14 2016-12-30 Arkema France Composition a base de terpolymere electroactif
DK3271382T3 (da) * 2015-03-16 2020-05-04 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
JP7591342B2 (ja) 2016-06-08 2024-11-28 プレシゲン，インコーポレイテッド Ｃｄ３３特異的キメラ抗原受容体
KR20230107408A (ko) 2016-07-29 2023-07-14 주노 쎄러퓨티크스 인코퍼레이티드 항-cd19 항체에 대한 항-이디오타입 항체
US11883430B2 (en) 2016-11-09 2024-01-30 Musc Foundation For Research Development CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
JP7288401B2 (ja) 2017-01-10 2023-06-07 プレシゲン，インコーポレイテッド 新規の遺伝子スイッチ発現系を介したポリペプチドの発現のモジュレーション
US11285196B2 (en) 2017-03-13 2022-03-29 Eslam Abbas Baseuny Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof
IL269716B2 (en) 2017-04-18 2025-07-01 Fujifilm Cellular Dynamics Inc Antigen-specific immune effector cells
JP7262403B2 (ja) 2017-06-07 2023-04-21 プレシゲン，インコーポレイテッド 新規の細胞タグの発現
KR102823603B1 (ko) 2017-10-12 2025-06-23 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 면역요법을 위한 t 세포 수용체
CN111918661A (zh) 2018-02-21 2020-11-10 得克萨斯大学体系董事会 用于活化和扩增自然杀伤细胞的方法及其用途
EA202191463A1 (ru) 2018-11-28 2021-10-13 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде
MX2021006393A (es) 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
JP2023500671A (ja) 2019-11-06 2023-01-10 ベイラー カレッジ オブ メディスン がんのｔ細胞治療のための細胞傷害性エフェクターメモリーｔ細胞の産生方法
US20230079539A1 (en) 2020-02-10 2023-03-16 Board Of Regents, The University Of Texas System Methods for rapid cloning and expression of hla class i cells
BR112022024027A2 (pt) 2020-05-27 2023-02-07 Antion Biosciences Sa Moléculas adaptadoras para redirecionar células t car para um antígeno de interesse
WO2022140759A2 (en) 2020-12-23 2022-06-30 Janssen Biotech, Inc. Neoantigen peptide mimics
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242687A (en) 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
JP2683461B2 (ja) * 1991-07-05 1997-11-26 住友電気工業株式会社 光ファイバケーブルの製造方法
US5583031A (en) * 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
US5314813A (en) * 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
WO1996012009A2 (en) * 1994-10-14 1996-04-25 Tykocinski Mark L Methods for engineering antigen-presenting cells
DE69737070T2 (de) * 1996-05-23 2007-06-21 The Scripps Research Institute, La Jolla Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten

Also Published As

Publication number Publication date
JP2012143245A (ja) 2012-08-02
DE69737070T2 (de) 2007-06-21
AU3210397A (en) 1998-01-05
ES2278390T3 (es) 2007-08-01
EP0969865B1 (en) 2006-12-06
EP0969865A4 (en) 2001-07-11
CA2254975A1 (en) 1997-12-11
ATE347588T1 (de) 2006-12-15
JP5006998B2 (ja) 2012-08-22
IL126843A (en) 2007-06-17
US20050054090A1 (en) 2005-03-10
EP0969865A1 (en) 2000-01-12
US7439335B2 (en) 2008-10-21
JP2000511898A (ja) 2000-09-12
CA2254975C (en) 2008-12-16
US20050059144A1 (en) 2005-03-17
US7074617B1 (en) 2006-07-11
PT969865E (pt) 2007-02-28
US7402430B2 (en) 2008-07-22
WO1997046256A1 (en) 1997-12-11
US6355479B1 (en) 2002-03-12
DE69737070D1 (de) 2007-01-18
AU723355B2 (en) 2000-08-24
IL126843A0 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
DK0969865T3 (da) Systemer til præsentation af MHC-antigener af klasse II og fremgangsmåder til aktivering af CD4+-T-celller
DK0814838T3 (da) Antigenpræsenterende system og aktivering af T-celler
ATE347585T1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
ES2059446T3 (es) Composicion de copolimero bloque hidrogenado especifico y procedimiento para su fabricacion.
WO2000023053A3 (en) Artificial antigen-specific cells and related methods
DK0716689T3 (da) Fremgangsmåde til fremstilling og dyrkning af hæmatopoietiske forløberceller
DK0975333T3 (da) Alginatgel med langvarig frigörelse
BR9806764A (pt) Moléculas mutantes ctla4 solúveis e usos das mesmas.
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
PT98571A (pt) Dispositivos para a libertacao controlada que utilizam membranas polimerizadas interfacialmente e de processos para a sua preparacao
ES2152424T3 (es) Complejos del mhc y usos de los mismos.
AU7979094A (en) Methods and compositions for microencapsulation of adjuvants
DK1634949T3 (da) Fremgangsmåde til at generere aktiverede T-celler og antigen-inkuberede antigen-præsenterende celler
MX9301742A (es) Copolimeros de bloques de fluorosilicona y metodo para su preparacion.
AR245684A1 (es) Procedimiento mejorado de hidrogenolisis/deshidrohalogenacion
BR9713498A (pt) Identificação de interações de ligação singulares entre alguns anticorpos e os antìgenos co-estimulatórios b7.1 e b7.2 humanos
ES2153468T3 (es) Preparaciones cosmeticas y/o farmaceuticas con sensacion cutanea mejorada.
ATE173294T1 (de) Immortalisierung von dendritischen zellen mit dem v-myc onkogen
NL194083B (nl) Verenigbare polymeermengsels van twee verschillende polymethacrylaten respectievelijk polyacrylaten, alsmede de toepassing daarvan.
DK0717744T3 (da) Fremgangsmåde til fremstilling af 9-(-2-hydroxy)-ethoxymethylguanin
AU6643894A (en) Elastic membrane
NO960710D0 (no) Nye tripeptider nyttige i immun- og CNS-terapi
PT93337A (pt) Ensaio para o tratamento e doencas autoimunitarias
Barber Occupational stressors and work behavior types of Cooperative Extension Service midmanagers
ES2015117A6 (es) Sistema de estructura con tensor incorporado para rotulos laminares.